Zacks Investment Research upgraded shares of Nabriva Therapeutics (NASDAQ:NBRV) from a hold rating to a buy rating in a report issued on Tuesday morning, Zacks.com reports. They currently have $2.75 price objective on the biotechnology company’s stock.
According to Zacks, “Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). “
Several other brokerages have also recently commented on NBRV. Needham & Company LLC reiterated a buy rating and issued a $10.00 price target (down previously from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. HC Wainwright boosted their price target on shares of Palatin Technologies from $5.00 to $6.00 and gave the stock a buy rating in a research note on Thursday, May 9th. ValuEngine cut shares of Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. Gabelli reiterated a buy rating on shares of Flushing Financial in a research note on Thursday, May 2nd. Finally, BidaskClub cut shares of Zebra Technologies from a hold rating to a sell rating in a research note on Friday, May 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $7.34.
NBRV stock traded up $0.10 during mid-day trading on Tuesday, hitting $2.44. The company had a trading volume of 264,322 shares, compared to its average volume of 458,352. The company has a market capitalization of $2.26 billion, a P/E ratio of -1.49 and a beta of 2.40. Nabriva Therapeutics has a 12-month low of $1.12 and a 12-month high of $3.58. The company has a quick ratio of 5.55, a current ratio of 5.55 and a debt-to-equity ratio of 0.40. The firm’s 50-day moving average price is $2.25.
Nabriva Therapeutics (NASDAQ:NBRV) last announced its quarterly earnings results on Friday, May 10th. The biotechnology company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $0.56 million. Nabriva Therapeutics had a negative net margin of 3,194.72% and a negative return on equity of 119.75%. On average, research analysts forecast that Nabriva Therapeutics will post -1.14 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC grew its stake in Nabriva Therapeutics by 77.0% in the 1st quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock valued at $7,958,000 after acquiring an additional 1,418,800 shares during the last quarter. Fosun International Ltd acquired a new stake in Nabriva Therapeutics in the 1st quarter valued at about $1,593,000. HRT Financial LLC acquired a new stake in Nabriva Therapeutics in the 4th quarter valued at about $31,000. Jane Street Group LLC acquired a new stake in Nabriva Therapeutics in the 4th quarter valued at about $29,000. Finally, Paloma Partners Management Co acquired a new stake in Nabriva Therapeutics in the 4th quarter valued at about $54,000. Hedge funds and other institutional investors own 3.02% of the company’s stock.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
See Also: What is a stock split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.